The $450 price target has become a focal point for Elevance Health, Inc. (ELV) because it closely aligns with the consensus analyst estimate. According to data from S&P Global, 22 analysts covering the stock have set an average 12-month price target of approximately $449, with individual forecasts ranging from $393 to $492. This clustering of professional expectations makes $450 a natural psychological and analytical milestone — a level that, if reached, would confirm that the company's margin recovery and strategic repositioning are gaining traction.
Elevance Health, formerly known as Anthem, Inc., is one of the largest health benefits companies in the United States. Headquartered in Indianapolis, the company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It serves approximately 45 million medical members across commercial, Medicare, Medicaid, and Federal Employee Program (FEP) plans under brands including Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon. The company rebranded in 2022 to reflect its broader focus beyond traditional health insurance into integrated care delivery and pharmacy benefit management.
As of the most recent close, ELV shares trade at approximately $373, giving the company a market capitalization of roughly $81 billion. The stock has experienced a wide trading range over the past 52 weeks, touching a low of approximately $274 and a high of roughly $436. After reaching that 52-week high in mid-July 2026, shares pulled back sharply — falling roughly 8.5% in a single session following the company's Q2 earnings release — despite results that beat expectations on both the top and bottom lines. The sell-off reflected investor concerns about margin pressure in Medicaid and the impact of one-time benefit adjustments rather than any fundamental deterioration in the business.
Several catalysts could propel ELV toward the $450 target. The company's Q2 2026 adjusted earnings per share of $7.45 handily exceeded Wall Street's $6.21 consensus, while revenue of $49.8 billion also topped estimates. Elevance raised its full-year 2026 EPS and operating cash flow outlook, signaling management confidence in the trajectory. Guggenheim analyst research points to continued benefits from a restructured Medicare Advantage (MA) product portfolio and favorable health insurance exchange trends. The firm projects consistent EPS growth above 12% for 2027 and beyond, underpinning its $455 price target.
Additionally, improved Medicaid reimbursement rates in multiple states and the company's strategic decision to exit underperforming Medicaid markets are expected to support margin recovery. On the capital allocation front, Elevance has been aggressively repurchasing shares and has raised its dividend for 15 consecutive years, demonstrating strong free cash flow generation and a commitment to returning capital to shareholders.
The analyst community remains broadly constructive on ELV. Of 22 analysts surveyed, 14 rate the stock a Strong Buy or Buy, while 8 maintain a Hold rating; there are zero Sell recommendations. Recent price target revisions have skewed decisively higher: Bernstein raised its target to $488, Deutsche Bank upgraded the stock to Buy with a $498 target, J.P. Morgan moved to $476, and Cantor Fitzgerald lifted its estimate to $450. Truist Financial and TD Cowen both set targets at or above $450. The highest target among major firms currently stands at $498, implying the $450 level is well within the zone analysts consider achievable.
Several headwinds could keep ELV from reaching $450. Medicaid enrollment headwinds remain a concern — Wolfe Research noted that Elevance maintains the most conservative industry guidance on Medicaid enrollment for 2026, projecting a decline of approximately 8%. Medical cost trends, while described as manageable in recent quarters, contain uncertainty around specialty drug spending and behavioral health utilization. Furthermore, the Centers for Medicare & Medicaid Services (CMS) imposed a compliance deadline tied to Medicare Advantage risk adjustment data; while Elevance has made progress toward resolution, the overhang has contributed to periodic bouts of selling pressure.
The company's large Medicare risk adjustment accrual — essentially a reserve set aside for potential repayment obligations — remains a material uncertainty. Regulatory scrutiny of managed care organizations more broadly, particularly around risk adjustment practices, could resurface as a headline risk at any time.
From a technical analysis perspective, the $436 zone represents the most immediate resistance — it marks the 52-week high reached in mid-July 2026 and the highest price traded since the stock's decline from its all-time peak of $544 set in September 2024. A sustained breakout above $436 would signal that buyers have absorbed overhead supply and could open a path toward the psychologically important $450 level. On the downside, support appears near $365, which coincides with the lower end of a recent trading range and represents an area where buyers previously stepped in. The stock's 200-day moving average, near $347, provides a deeper support reference that has held throughout 2026.
Investors seeking a data-driven edge in timing their decisions around stocks like ELV may benefit from AI Daily Buy/Sell Signals. This platform leverages artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven pattern recognition. By distilling large volumes of market data into actionable signals, the tool helps traders identify emerging opportunities, track existing positions with greater efficiency, and stay ahead of shifting market trends without requiring constant manual analysis.
The $450 price target for Elevance Health appears realistic given the current fundamental and analyst backdrop, but reaching it will likely require a confluence of favorable developments. The company's improving margin profile, particularly in Medicare Advantage and commercial lines, combined with disciplined capital allocation and a stabilizing policy environment, provides a credible foundation for further upside. However, Medicaid enrollment attrition, regulatory compliance risks, and the potential for medical cost trend surprises remain meaningful obstacles. Investors should monitor quarterly medical loss ratio (MLR) trends — the percentage of premiums spent on medical claims — along with progress on CMS compliance resolution and the pace of Medicaid market exits. A decisive break above the $436 resistance level would be a strong technical signal that the market is pricing in a successful path to $450 and beyond.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ELV has been loosely correlated with UNH. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ELV jumps, then UNH could also see price increases.